Recent advances in the management of hepatocellular carcinoma.
Recent advances in the management of hepatocellular carcinoma.
复制标题
DOI：
10.3350/cmh.2023.0125
复制
发表时间：
2024-01
影响因子：
8.9
通讯作者：
Yang JD
中科院分区：
文献类型：
--
作者：
Sankar K;Gong J;Osipov A;Miles SA;Kosari K;Nissen NN;Hendifar AE;Koltsova EK;Yang JD
肝癌仍然是全球健康面临的挑战，是全球癌症死亡的第四大原因。肝细胞癌（HCC）是最常见的原发性肝癌类型，通常由慢性病毒感染（乙型和丙型肝炎）、非酒精性脂肪性肝炎、大量饮酒以及其他可能导致慢性炎症和肝硬化的因素诱发。在过去的几十年里，肝癌的全身治疗选择已经取得了重大进展，免疫检查点抑制剂和酪氨酸激酶抑制剂在肝功能保存的患者中获得了几项批准。这些进展已经改善了生存结果，对于那些具有敏感性肿瘤、肝功能充足和功能适合接受序贯治疗的患者，预期生存期超过18个月。一些正在进行和有希望的试验正在评估与新型全身药物的联合策略以及全身治疗与局部治疗的组合。鉴于这些试验，在不久的将来可以预见HCC治疗的进一步进展。
Liver cancer remains a challenge of global health, being the 4th leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and is usually precipitated by chronic viral infections (hepatitis B and C), non-alcoholic steatohepatitis, heavy alcohol use, and other factors which may lead to chronic inflammation and cirrhosis of the liver. There have been significant advances in the systemic treatment options for HCC over the past decades, with several approvals of both immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with preserved liver function. These advances have led to improvement in survival outcomes, with expected survival of greater than 18 months, in those with sensitive tumors, adequate liver function, and those functionally fit to receive sequential therapies. Several ongoing and promising trials are now evaluating combinational strategies with novel systemic agents and combinations of systemic therapy with locoregional therapy. In view of these trials, further advances in the treatment of HCC are foreseen in the near future.
登录
查看更多内容
立体定向全身放射治疗和免疫治疗与经动脉化疗栓塞治疗局部晚期肝细胞癌的联合治疗：倾向评分匹配分析。
影响因子：
4.7
作者：
Chiang CL;Chiu KW;Lee FA;Kong FS;Chan AC
通讯作者：
Chan AC
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
8.8
作者：
Iavarone, Massimo;Invernizzi, Federica;Reig, Maria
通讯作者：
Reig, Maria
影响因子：
158.5
作者：
Finn, Richard S.;Qin, Shukui;Cheng, Ann-Lii
通讯作者：
Cheng, Ann-Lii
影响因子：
168.9
作者：
Bruix, Jordi;Qin, Shukui;Han, Guohong
通讯作者：
Han, Guohong